"Molecular Switches" on mGluR Allosteric Ligands That Modulate Modes of Pharmacology

Por Wood, Michael R., Hopkins, Corey R., Brogan, John T., Conn, P. Jeffrey, Lindsley, Craig W.
Publicado em 2011

Allosteric modulation of the M(1) muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer′s disease

Por Melancon, Bruce J., Tarr, James C., Panarese, Joseph D., Wood, Michael R., Lindsley, Craig W.
Publicado em 2013

THE ANTIPSYCHOTIC POTENTIAL OF MUSCARINIC ALLOSTERIC MODULATION

Por Bridges, Thomas M., LeBois, Evan P., Hopkins, Corey R., Wood, Michael R., Jones, Carrie K., Conn, P. Jeffrey, Lindsley, Craig W.
Publicado no Drug News Perspect (2010)

Allosteric Modulation of 7 Transmembrane Spanning Receptors: Theory, Practice and Opportunities for CNS Drug Discovery()

Por Melancon, Bruce J., Hopkins, Corey R., Wood, Michael R., Emmitte, Kyle A., Niswender, Colleen M., Christopoulos, Arthur, Conn, P. Jeffrey, Lindsley, Craig W.
Publicado em 2012

M(5) Receptor Activation Produces Opposing Physiological Outcomes in Dopamine Neurons Depending on the Receptor's Location

Por Foster, Daniel J., Gentry, Patrick R., Lizardi-Ortiz, Jose E., Bridges, Thomas M., Wood, Michael R., Niswender, Colleen M., Sulzer, David, Lindsley, Craig W., Xiang, Zixiu, Conn, P. Jeffrey
Publicado em 2014

Chemical Modification of the M(1) Agonist VU0364572 Reveals Molecular Switches in Pharmacology and a Bitopic Binding Mode

Por Digby, Gregory J., Utley, Thomas J., Lamsal, Atin, Sevel, Christian, Sheffler, Douglas J., Lebois, Evan P., Bridges, Thomas M., Wood, Michael R., Niswender, Colleen M., Lindsley, Craig W., Conn, P. Jeffrey
Publicado em 2012

Further optimization of the M(5) NAM MLPCN probe ML375: Tactics and challenges

Por Kurata, Haruto, Gentry, Patrick R., Kokubo, Masaya, Cho, Hyekyung P., Bridges, Thomas M., Niswender, Colleen M., Byers, Frank W., Wood, Michael R., Daniels, J. Scott, Conn, P. Jeffrey, Lindsley, Craig W.
Publicado no Bioorg Med Chem Lett (2014)

Spirocyclic replacements for the isatin in the highly selective, muscarinic M(1) PAM ML137: the continued optimization of an MLPCN probe molecule

Por Poslusney, Michael S., Melancon, Bruce J., Gentry, Patrick R., Sheffler, Douglas J., Bridges, Thomas M., Utley, Thomas J., Daniels, J. Scott, Niswender, Colleen M., Conn, P. Jeffrey, Lindsley, Craig W., Wood, Michael R.
Publicado em 2013

Synthesis and biological characterization of a series of novel diaryl amide M(1) antagonists

Por Poslusney, Michael S., Sevel, Christian, Utley, Thomas J., Bridges, Thomas M., Morrison, Ryan D., Kett, Nathan R., Sheffler, Douglas J., Niswender, Colleen M., Daniels, J. S., Conn, P. J., Lindsley, Craig W., Wood, Michael R.
Publicado em 2012

Discovery of ML326: the first sub-micromolar, selective M(5) PAM

Por Gentry, Patirck R., Bridges, Thomas M., Lamasal, Atin, Vinson, Paige N., Smith, Emery, Chase, Peter, Hodder, Peter S., Engers, Julie L., Niswender, Colleen M., Daniels, J. Scott, Conn, P. Jeffrey, Wood, Michael R., Lindsley, Craig W.
Publicado em 2013

Further exploration of M(1) allosteric agonists: Subtle structural changes abolish M(1) allosteric agonism and result in pan-mAChR orthosteric antagonism

Por Sheffler, Douglas J., Sevel, Christian, Le, Uyen, Lovell, Kimberly M., Tarr, James C., Carrington, Sheridan J. S., Cho, Hyekyung P., Digby, Gregory J., Niswender, Colleen M., Conn, P. Jeffrey, Hopkins, Corey R., Wood, Michael R., Lindsley, Craig W.
Publicado em 2012

Development of a Highly Potent, Novel M(5) Positive Allosteric Modulator (PAM) Demonstrating CNS Exposure: 1-((1H-Indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piper...

Por Gentry, Patrick R., Kokubo, Masaya, Bridges, Thomas M., Noetzel, Meredith J., Cho, Hyekyung P., Lamsal, Atin, Smith, Emery, Chase, Peter, Hodder, Peter S., Niswender, Colleen M., Daniels, J. Scott, Conn, P. Jeffrey, Lindsley, Craig W., Wood, Michael R.
Publicado em 2014

Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M(4))

Por Smith, Emery, Chase, Peter, Niswender, Colleen M., Utley, Thomas J., Sheffler, Douglas J., Noetzel, Meredith J., Lamsal, Atin, Wood, Michael R., Conn, P. Jeffrey, Lindsley, Craig W., Madoux, Franck, Acosta, Mary, Scampavia, Louis, Spicer, Timothy, Hodder, Peter
Publicado no J Biomol Screen (2015)

Discovery and optimization of a novel, selective and brain penetrant M(1) positive allosteric modulator (PAM): the development of ML169, an MLPCN Probe

Por Reid, Paul R., Bridges, Thomas M., Sheffler, Douglas J., Cho, Hyekyung P., Lewis, L. Michelle, Days, Emily, Daniels, J. Scott, Jones, Carrie K., Niswender, Colleen M., Weaver, C. David, Conn, P. Jeffrey, Lindsley, Craig W., Wood, Michael R.
Publicado em 2010

Isatin replacements applied to the highly selective, muscarinic M(1) PAM ML137: Continued optimization of an MLPCN probe molecule

Por Melancon, Bruce J., Poslusney, Michael S., Gentry, Patrick R., Tarr, James C., Sheffler, Douglas J., Mattmann, Margrith E., Bridges, Thomas M., Utley, Thomas J., Daniels, J. Scott, Niswender, Colleen M., Conn, P. Jeffrey, Lindsley, Craig W., Wood, Michael R.
Publicado em 2012

Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012

Por Melancon, Bruce J., Utley, Thomas J., Sevel, Christian, Mattmann, Margrith E., Cheung, Yiu-Yin, Bridges, Thomas M., Morrison, Ryan D., Sheffler, Douglas J., Niswender, Colleen M., Daniels, J. Scott, Conn, P. Jeffrey, Lindsley, Craig W., Wood, Michael R.
Publicado em 2012

Discovery of the first M(5)-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-...

Por Gentry, Patrick R., Kokubo, Masaya, Bridges, Thomas M., Kett, Nathan R., Harp, Joel M., Cho, Hyekyung P., Smith, Emery, Chase, Peter, Hodder, Peter S., Niswender, Colleen M., Daniels, J. Scott, Conn, P. Jeffrey, Wood, Michael R., Lindsley, Craig W.
Publicado em 2013

Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354

Por Wen, Wandong, Young, Summer E., Duvernay, Matthew T., Schulte, Michael L., Nance, Kellie D., Melancon, Bruce J., Engers, Julie, Locuson, Charles W., Wood, Michael R., Daniels, J. Scott, Wu, Wenjun, Lindsley, Craig W., Hamm, Heidi E., Stauffer, Shaun R.
Publicado no Bioorg Med Chem Lett (2014)

Development of a Highly Selective, Orally Bioavailable and CNS Penetrant M(1) Agonist Derived from the MLPCN Probe ML071

Por Lebois, Evan P., Digby, Gregory J., Sheffler, Douglas J., Melancon, Bruce J., Tarr, James C., Cho, Hyekyung P., Miller, Nicoel R., Morrison, Ryan, Bridges, Thomas M., Xiang, Zixiu, Daniels, J. Scott, Wood, Michael R., Conn, P. Jeffrey, Lindsley, Craig W.
Publicado em 2011

Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012

Por Melancon, Bruce J., Lamers, Alexander P., Bridges, Thomas M., Sulikowski, Gary A., Utley, Thomas J., Sheffler, Douglas J., Noetzel, Meredith J., Morrison, Ryan D., Daniels, J. Scott, Niswender, Colleen M., Jones, Carrie K., Conn, P. Jeffrey, Lindsley, Craig W., Wood, Michael R.
Publicado em 2011